KZR — Kezar Life Sciences Share News
0.000.00%
Last trade - 00:00Brief: Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold On Portola Phase 2A Trial Evaluating Zetomipzomib
Brief: Kezar Life Sciences Q1 Net Income USD -16.556 Million
Kezar Life Sciences Inc expected to post a loss of $2.60 a share - Earnings Preview
Kezar Life Sciences Inc reports results for the quarter ended December 31 - Earnings Summary
Kezar Life Sciences Inc expected to post a loss of $2.88 a share - Earnings Preview
Brief: Kezar Life Sciences Files For Mixed Shelf Of Upto $400 Million
Kezar Life Sciences Inc reports results for the quarter ended September 30 - Earnings Summary
U.S. RESEARCH ROUNDUP- AMN Healthcare Services, Chart Industries, Home Depot
Brief: Kezar Life Sciences Q3 Operating Expenses USD 21.948 Million
Kezar Life Sciences Inc expected to post a loss of $3.15 a share - Earnings Preview
Brief: Kezar Life Sciences Announces 1-For-10 Reverse Stock Split
U.S. STOCKS ON THE MOVE-Avery Dennison, Snap-On, Avadel Pharma
U.S. STOCKS ON THE MOVE-Avery Dennison, Snap-On, Avadel Pharma
Kezar Life Sciences falls on terminating mid-stage lupus drug trial
Kezar to discontinue mid-stage trial for lupus treatment (updated)
Kezar to discontinue mid-stage trial for lupus treatment
Brief: Kezar Board Unanimously Rejects Unsolicited Concentra Proposal And Adopts Limited Duration Stockholder Rights Plan
Brief: Kezar Life Sciences Announces Positive IDMC Safety Review Of Portola Trial Of Zetomipzomib In Patients With Autoimmune Hepatitis And Provides Palizade Update
Brief: Kezar Confirms Receipt Of Unsolicited, Non-Binding Acquisition Proposal